Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment

  title={Variation of serum uric acid levels in multiple sclerosis during relapses and immunomodulatory treatment},
  author={{\'A}ngel Luis Guerrero and J. Mart{\'i}n-Polo and E. Laherr{\'a}n and Fernando Guti{\'e}rrez and Fernando Iglesias and Maria A. Tejero and Manuel Rodr{\'i}guez-Gallego and C Del Moral Alcazar},
  journal={European Journal of Neurology},
Uric acid (UA), a product of purine metabolism, may be an antioxidant, perhaps acting as a scavenger of peroxynitrite. Patients with gout have a reduced incidence of multiple sclerosis (MS). A number of studies found that patients with MS have low serum levels of UA, although it has not been established whether this represents a primary deficit or a secondary effect. UA has also been proposed as a marker of disease activity and response to immunosuppressive or immunomodulatory treatment. We… 

Serum Uric Acid Levels in Patients with Relapsing-Remitting Multiple Sclerosis

Serum UA levels did not correlate with clinical activity, EDSS score and disease duration either in relapse or remitting or both of them, and suggests serum uric acid levels may affect neither pathogenesis of MS nor activity of disease.

Serum uric acid levels in multiple sclerosis patients inversely correlate with disability

This is the first description of an inverse correlation of serum UA levels with disability as assessed by EDSS score, which is associated with clinical relapse in multiple sclerosis patients.

Association of serum bilirubin and uric acid levels changes during neuroinflammation in patients with initial and relapsed demyelination attacks

The obtained results point to the importance of endogenous antioxidants in the outbreak and course of neuroinflammation and could be favorable for the new pathogenetically conditioned neuroinflammatory therapy concepts.

Serum uric acid levels in patients with multiple sclerosis: a meta-analysis

The study suggests that UA is relevant to MS, and whether the administration of UA levels by inosine might be considered as a novel treatment strategy for MS is needed.

Low Serum Urate Levels Are Associated to Female Gender in Multiple Sclerosis Patients

The findings suggest that low urate levels could be of significance in predominantly inflammatory phases of MS even at the early stage and mainly in females.

Cerebrospinal fluid and serum uric acid levels in patients with multiple sclerosis

The results support the significance of UA in the pathogenesis of multiple sclerosis and suggest CSF UA concentrations may not be a reliable marker of disease activity in MS since its concentration is dependent on leakage of UA molecules from serum through the damaged BBB and the balance between consumption/production within the central nervous system (CNS).

Serum Metabolic Profile in Multiple Sclerosis Patients

The concomitant increase in circulating creatinine, malondialdehyde, nitrite, and nitrate, and decrease in ascorbic acid demonstrates that MS induces alteration in energy metabolism and in oxidants/antioxidants balance that can be monitored in serum of MS patients.

Influence of serum uric acid levels on prognosis and survival in amyotrophic lateral sclerosis: a meta-analysis

A meta-analysis of published studies comparing UA levels between ALS patients and controls revealed highly statistically significant lower UA levels in patients compared to controls, with very large total size effect, more prominent in men.

Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon β in relapsing- remitting Multiple Sclerosis (ASIIMS) trial

It is concluded that endogenous neuroprotective mechanisms recently identified in multiple sclerosis are complex and uric acid does not reflect the entire story and interferon β alone alone did not provide any additional benefit on accumulation of disability.

Reduced serum uric acid levels in neuromyelitis optica: serum uric acid levels are reduced during relapses in NMO

The aim of this study was to investigate the association between serum UA levels and disease activity in neuromyelitis optica.



Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis

Investigating serum UA changes during open-label treatment of relapsing MS with GAA found increasing UA, a natural inhibitor of free radicals, may represent a mechanism of action of glatiramer acetate in MS.

Serum uric acid and multiple sclerosis

The view that reduced UA in MS is a primary, constitutive loss of protection against oxidative agents, which deserves further pathogenetic elucidation aimed at future therapeutic strategies is favors the view.

High-dose Methylprednisolone Therapy in Multiple Sclerosis Increases Serum Uric Acid Levels

Serum uric acid levels before and after high-dose methylprednisolone treatment (intravenous 1 g/day/5 days) in multiple sclerosis patients are investigated to suggest that increasing the uric Acid concentration may represent one of the possible mechanisms of action of methylpredisonsolone inmultiple sclerosis.

Uric acid levels in sera from patients with multiple sclerosis

It is suggested that serum UA might serve as a possible marker of disease activity in MS and provide support to the potential beneficial therapeutic effect of radical-scavenging substances in MS.

Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors

The mode of action of inosine and inosinic acid in EAE is via their metabolism to UA, and the therapeutic effect on animals with active EAE was associated with increased UA, but not inOSine, levels in CNS tissue.

Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs. progressive multiple sclerosis

The results suggest that serum levels of uric acid and DHEAS, and apoE genotype do not differ between patients with a benign and progressive course of MS.

Serum uric acid levels in optic neuritis

Reduced antioxidant reserve is possibly an early patho genic mechanism in inflammatory demyelination, and raises the possibility that low uric acid levels could be an indicator of disease activity, since optic neuropathies of other causes were not investigated.

Nonenzymatic antioxidants of blood in multiple sclerosis

Investigation of the plasma level of lipid peroxides expressed in terms of malone dialdehyde and changes in blood nonenzymatic antioxidants in multiple sclerosis patients with exacerbation or in remission suggests increased free radical production and consumption of the scavenger molecules during the active phase of the disease.

Uric acid, a natural scavenger of peroxynitrite, in experimental allergic encephalomyelitis and multiple sclerosis.

Uric acid treatment was found to have strong therapeutic effects in a dose-dependent fashion and diminish clinical signs of a disease resembling EAE in interferon-gamma receptor knockout mice, raising the possibility that hyperuricemia may protect against MS.